SAPHRIS

This brand name is authorized in United States. It is also authorized in Australia, Canada, Israel, New Zealand.

Active ingredients

The drug SAPHRIS contains one active pharmaceutical ingredient (API):

1	Asenapine UNII CU9463U2E2 - ASENAPINE MALEATE
	The mechanism of action of asenapine is not fully understood. However, based on its receptor pharmacology, it is proposed that the efficacy of asenapine is mediated through a combination of antagonist activity at D2 and 5-HT2A receptors. Actions at other receptors e.g. 5-HT1A, 5-HT1B, 5-HT2C, 5-HT6, 5-HT7, D3, and a2-adrenergic receptors, may also contribute to the clinical effects of asenapine.
	Read more about Asenapine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SAPHRIS Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05AH05	Asenapine	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AH Diazepines, oxazepines and thiazepines
Discover more medicines within N05AH05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	5140M, 5141N
CA	Health Products and Food Branch	02374803, 02374811
IL	מִשְׂרַד הַבְּרִיאוּת	6837, 6838
NZ	Medicines and Medical Devices Safety Authority	15151, 15152
US	FDA, National Drug Code	0456-2402, 0456-2405, 0456-2410